CD274 and cancer: Conventional treatments such as chemotherapy have yielded modest results, with overall survival (OS) rates remaining low and objective response rates (ORR) varying significantly depending on the specific histological subtype.1 Recent developments in immunotherapy, particularly immune checkpoint blockade (ICB) using anti-PD1 and PD-L1 inhibitors, have raised hopes for better treatment outcomes in cancer therapy, including STS.